A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
Shuo LinMu ChenWanling ChenKeyi LinPanwei MuBilian ZhuWen XuManman WangJianping WengLongyi ZengPublished in: Journal of diabetes research (2018)
Short-term insulin glargine plus OHAs may be an alternative to CSII for initial intensive therapy in people with newly diagnosed type 2 diabetes.